Summary
Abbott Laboratories' third quarter 2001 report shows a significant increase in Net Sales, driven primarily by the recent acquisition of the pharmaceutical business of BASF (Knoll Pharmaceuticals) for approximately $7.1 billion. This acquisition substantially impacted the company's financial structure, leading to increased debt and operating expenses, including higher amortization of intangibles and goodwill. While revenue growth is evident, especially in the Pharmaceutical and International segments, earnings per share saw a slight decrease compared to the prior year due to these acquisition-related costs and restructuring charges. Investors should note the substantial investment in Research and Development, indicating a continued focus on innovation. However, the company is also navigating several legal proceedings, including antitrust suits related to drug pricing and the ongoing investigation and settlement concerning TAP Pharmaceutical Products Inc.'s marketing of LUPRON. Management believes these legal matters, while significant, will not have a material adverse effect on the company's financial position. The company is also facing regulatory scrutiny on its diagnostics manufacturing operations under a consent decree with the FDA.
Key Highlights
- 1Net Sales increased by 26.0% to $4.18 billion for the third quarter and 17.9% to $11.84 billion for the nine months ended September 30, 2001, largely due to the acquisition of BASF's pharmaceutical business.
- 2The acquisition of BASF's pharmaceutical business (Knoll) for $7.1 billion in March 2001 significantly impacted the balance sheet, with a large portion allocated to intangible assets ($3.5B) and goodwill ($1.9B).
- 3Earnings per diluted share decreased slightly to $0.40 for the third quarter of 2001, compared to $0.42 in the prior year, primarily due to increased operating expenses from the acquisition and restructuring charges.
- 4Research and Development expenses increased by 25.8% for the third quarter and 11.5% for the nine months (excluding acquired in-process R&D), signaling continued investment in innovation.
- 5Significant restructuring charges of $167.4 million were recorded in 2001 related to the integration of the acquired pharmaceutical business and the closure of a manufacturing operation.
- 6Abbott incurred a substantial charge of $1.187 billion for acquired in-process research and development related to the BASF acquisition.
- 7The company is actively involved in multiple legal proceedings, including antitrust investigations and a significant settlement by its joint venture, TAP Pharmaceutical Products Inc., related to LUPRON marketing practices.